



<https://africanjournalofbiomedicalresearch.com/index.php/AJBR>

Afr. J. Biomed. Res. Vol. 28(4s) (October 2025); 361-369

Research Article

Beyond Memory: The Multifaceted Pharmacological Potential Of Bacopa Monnieri

Anna Maria Modzelewska^{1*}, Michał Szczupak², Michał Wycik³, Kinga Rydel⁴, Urban Stanisław Matyjasik⁵, Gabriela Kondratiuk⁶, Hubert Chmielewski⁷, Julia Komar⁸, Martyna Tyszek⁹, Adam Zysk¹⁰, Wiktor Modzelewski¹¹

^{1*}University Clinical Hospital in Białystok ul. M. C. Skłodowskiej 24a, 15-276 Białystok, Poland

ORCID: <https://orcid.org/0009-0007-1563-8946>, E-mail: a.modzelewska1313@gmail.com

²University Clinical Hospital in Białystok ul. M. C. Skłodowskiej 24a, 15-276 Białystok, Poland

ORCID: <https://orcid.org/0009-0005-5112-6978>, E-mail: szczupak.michal152@gmail.com

³University Clinical Hospital in Białystok ul. M. C. Skłodowskiej 24a, 15-276 Białystok, Poland

ORCID: <https://orcid.org/0009-0007-3052-9924>, E-mail: michalwycik98@gmail.com

⁴Śniadeckiego Voivodeship Hospital in Białystok, ul. M. C. Skłodowskiej 26, 15-278 Białystok, Poland

ORCID: <https://orcid.org/0009-0007-5100-1512>, E-mail: kingarydel@icloud.com

⁵Lower Silesian Oncology Center in Wrocław, plac Hirszfelda 12, 53-413 Wrocław, ORCID:

<https://orcid.org/0009-0004-7111-2541>, E-mail: urban.matyjasik2323@gmail.com

⁶Medical University of Białystok, Jana Kilińskiego 1, 15-089 Białystok, ORCID: <https://orcid.org/0009-0009-4181-731X>

⁷Medical University of Białystok, Jana Kilińskiego 1, 15-089 Białystok, ORCID: <https://orcid.org/0009-0000-5697-518X>, E-mail: hubertchmielewski25@gmail.com

⁸Medical University of Białystok, Jana Kilińskiego 1, 15-089 Białystok, ORCID: <https://orcid.org/0009-0008-9104-7934>, E-mail: julciakomar@gmail.com

⁹Medical University of Białystok, Jana Kilińskiego 1, 15-089 Białystok, ORCID: <https://orcid.org/0009-0002-9626-941X>, E-mail: m.tyszek111@gmail.com

¹⁰Southern Hospital in Warsaw, Rotmistrza Witolda Pileckiego 99, 02-781 Warszawa, ORCID:

<https://orcid.org/0009-0006-0425-2493>, E-mail: adzymail00@gmail.com

¹¹Medical University of Białystok, Jana Kilińskiego 1, 15-089 Białystok, ORCID: <https://orcid.org/0009-0008-5630-726X>, E-mail: wiktormodzelewski13@gmail.com

***Corresponding Author:** Anna Maria Modzelewska

^{*}University Clinical Hospital in Białystok ul. M. C. Skłodowskiej 24a, 15-276 Białystok, Poland

ORCID: <https://orcid.org/0009-0007-1563-8946>, E-mail: a.modzelewska1313@gmail.com

Abstract

Purpose of the research: This study aims to provide a comprehensive review of the pharmacological effects, mechanisms of action, clinical benefits, and safety profile of *Bacopa monnieri*, with a particular emphasis on its cognitive-enhancing, neuroprotective, adaptogenic, and cardioprotective properties.

Materials and methods: A narrative literature review methodology was employed. Scientific publications from indexed databases such as PubMed, ScienceDirect and Google Scholar were analyzed, with a focus on clinical trials, in vivo and in vitro studies on *Bacopa monnieri* and its active constituents.

Results: The findings demonstrate that *Bacopa monnieri* exerts cognitive benefits primarily through cholinergic modulation, neurogenesis, antioxidant activity, and anti-inflammatory mechanisms. It has shown promise in clinical trials for enhancing memory, reducing anxiety and depressive symptoms, and protecting against cardiovascular and hepatic injury. The herb also exhibits immunomodulatory and adaptogenic effects, and recent evidence suggests a role in telomere preservation and HPA axis regulation. It is generally well tolerated, although potential interactions with cytochrome P450-metabolized drugs warrant caution.

Conclusion: Bacopa monnieri is a well-researched medicinal herb with multiple mechanisms of action supporting its traditional use in cognitive and general health. Evidence from clinical and preclinical studies confirms its potential as a safe and effective natural agent for enhancing brain function, managing stress-related disorders, and providing systemic protection.

Keywords: Bacopa monnieri, cognitive enhancement, neuroprotection, antioxidants, adaptogens, herbal medicine, clinical trials, anxiety, depression, cardiovascular health

Acceptance -10/10/2025

Received- 06/10/2025

DOI: <https://doi.org/10.53555/AJBR.v28i4S.8522>

© 2025 The Author(s).

This article has been published under the terms of Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0), which permits noncommercial unrestricted use, distribution, and reproduction in any medium, provided that the following statement is provided. "This article has been published in the African Journal of Biomedical Research"

1. Introduction.

Bacopa monnieri (BM), also known as Brahmi or water hyssop, is a creeping herb native to South Asia and widely recognized in Ayurvedic medicine for its ability to enhance cognition and support neurological health. Traditionally used as a brain tonic, Bacopa monnieri has been employed for centuries to improve memory, reduce anxiety, and manage neurological and systemic conditions such as epilepsy, inflammation, and respiratory issues. The plant's therapeutic applications are primarily attributed to its complex phytochemical composition, rich in saponins (notably bacoside A and B), alkaloids, flavonoids, and triterpenes.

Scientific interest in Bacopa monnieri has grown considerably due to increasing evidence supporting its nootropic, antioxidant, and anti-inflammatory properties. Advanced analytical techniques have confirmed the presence of key compounds such as bacoside I, taraxerone, betulinic acid, and hersaponin, which exhibit multifaceted biological activity. Studies have shown that extracts of the plant can modulate neurotransmitter systems, stimulate neurogenesis, and influence pathways involved in synaptic plasticity, neuroprotection, and stress regulation.

Furthermore, Bacopa monnieri demonstrates substantial antioxidant capacity, supported by both enzymatic and non-enzymatic mechanisms. It upregulates key enzymes such as superoxide dismutase and catalase, reduces oxidative stress markers, and inhibits inflammatory mediators including COX-2 and iNOS. These mechanisms are essential in the prevention of neurodegenerative and cardiovascular diseases.

In addition to its central nervous system effects, the plant has been shown to exert hepatoprotective and cardioprotective actions, regulate the hypothalamic-pituitary-adrenal (HPA) axis, and even preserve telomere length and genomic stability in stress models. The adaptogenic properties of Bacopa monnieri further support its role in enhancing resilience to physical and psychological stress.

Given its broad therapeutic potential and favorable safety profile, Bacopa monnieri is gaining recognition as a valuable natural supplement. This review aims to synthesize current knowledge on the pharmacology,

clinical evidence, and safety of Bacopa monnieri to provide a scientific foundation for its application in modern integrative medicine.

2. Bioactive Compounds and Pharmacological Potential of Bacopa monnieri.

Bacopa monnieri (BM), commonly referred to as Brahmi or water hyssop, is a creeping, small-leaved herb that typically thrives in moist environments such as rice fields and waterlogged areas. It is native to South Asia and has been widely recognized in traditional medicinal systems, particularly Ayurveda, for its cognitive and restorative properties. The plant has long been used as a brain tonic to enhance memory and intellectual capacity, and has also been employed in the treatment of various conditions including anxiety, epilepsy, fever, asthma, and inflammation [1, 2]

Traditionally categorized as a nootropic herb, Bacopa monnieri has attracted scientific attention due to its broad spectrum of bioactive constituents. Phytochemical analyses of the whole plant have revealed a rich chemical profile consisting primarily of saponins, alkaloids, flavonoids, and triterpenes. Among these, the saponins known as bacoside A and bacoside B are considered the most significant, as they are believed to contribute to many of the plant's pharmacological activities, particularly those related to cognitive support. Additional compounds such as hersaponin, taraxerone, and betulinic acid have also been identified through chromatographic and spectroscopic techniques [1, 2]

The presence of taraxerone and betulinic acid, two pentacyclic triterpenoids isolated from the plant's methanolic extract, further supports the therapeutic potential of Bacopa monnieri. These compounds were identified using advanced techniques such as column chromatography and nuclear magnetic resonance (NMR) spectroscopy, which confirmed their structural characteristics. The diversity of these phytochemicals suggests that the plant contains multiple classes of bioactive molecules with potential applications in natural medicine [1, 2]

In addition to its internal use, Bacopa monnieri has also demonstrated utility in various in vitro biological assays. Extracts and solvent fractions of the plant have shown

activity in antioxidant, anti-inflammatory, antimicrobial, and thrombolytic assays. These findings, although primarily preliminary, support the traditional claims of the plant's therapeutic versatility [1, 2] In summary, *Bacopa monnieri* is a botanically well-established medicinal herb with a long history of use in traditional healthcare systems. Its complex phytochemical makeup, featuring notably bacosides and other secondary metabolites, underpins its widespread use for both cognitive enhancement and general health support. Continued investigation of its constituents contributes to a growing body of scientific evidence validating its ethnomedical significance.

3. Mechanisms.

3.1. Neurotransmission, Neurogenesis, Cholinergic Action.

Bacopa monnieri exerts its cognitive-enhancing effects through multiple mechanisms, primarily by modulating neurotransmission and promoting neurogenesis. One of the key neuropharmacological pathways involves the stimulation of neurogenesis in the hippocampal dentate gyrus. In adolescent mice, short-term administration of *Bacopa monnieri* extract (BME) significantly increased the proliferation of BrdU-positive cells and led to a sustained enhancement of spatial working memory, as demonstrated in Y-maze behavioral assays. These newly generated cells also differentiated into mature neurons, indicating that BME facilitates long-term neuroplastic changes in the hippocampus [3]

This neurogenic effect has been linked to the upregulation of several signaling pathways essential for neuronal survival and development. RNA sequencing revealed that BME treatment induced significant increases in the expression of genes associated with neurotrophin signaling, including NTRK2 and NTRK3, as well as the PI3K/Akt and CREB pathways, all of which are crucial for neurogenesis and cognitive function. Additionally, the cholinergic system was affected, with elevated expression of cholinergic receptors such as Chrm2 and Chrm5 and a nearly fourfold increase in choline acetyltransferase (ChAT) levels, suggesting enhanced cholinergic neurotransmission [3]

The active constituent bacopaside I has been identified as a key compound responsible for these effects. In vitro studies showed that bacopaside I significantly promoted the proliferation of neural progenitor cells in a concentration-dependent manner via activation of the ERK1 and Akt signaling cascades, further confirming its role in hippocampal neurogenesis and cognitive enhancement [3]

In parallel, broader evidence supports that *Bacopa monnieri* modulates neurotransmitter systems beyond the cholinergic axis. The herb is also known to affect dopaminergic and serotonergic transmission, potentially contributing to its anxiolytic and antidepressant properties. Importantly, *Bacopa monnieri* has been shown to enhance synaptic plasticity [4].

Collectively, these findings underscore *Bacopa monnieri*'s multifaceted action on the central nervous system, particularly its ability to stimulate neurogenesis, upregulate neurotrophic signaling, and enhance

cholinergic and synaptic function, positioning it as a promising candidate for cognitive enhancement and neuroprotection.

3.2 Antioxidant and Anti-inflammatory Properties of Bacopa monnieri.

Bacopa monnieri (BM) exerts substantial antioxidant and anti-inflammatory effects, which are considered fundamental to its neuroprotective and therapeutic potential. These properties are attributed to its rich phytochemical composition, including bacosides A and B, betulinic acid, loliolide, asiatic acid, and quercetin, which play crucial roles in modulating cellular stress and inflammatory responses [5].

BM demonstrates robust antioxidant activity through both enzymatic and non-enzymatic mechanisms. The enzymatic antioxidant defense includes the activities of superoxide dismutase (SOD), catalase (CAT), peroxidase (Px), ascorbate oxidase (AO), and polyphenol oxidase (PPO), all of which contribute to the detoxification of reactive oxygen species (ROS) [6]. Quantitative analysis has shown significant enzymatic activity in fresh stem extracts, with SOD at 10.83 ± 0.003 U/g FW, CAT at 41.03 ± 0.004 μ mol H₂O₂/min/mg protein, Px at 2.044 ± 0.003 U/mg protein/min, AO at 56.15 ± 0.003 U/mg protein/min, and PPO at 57.21 ± 0.003 U/mg protein/min [6]. These findings, along with the high antioxidant capacity observed in ethanol extracts ($IC_{50} = 16 \pm 0.3$ μ g/mL), suggest BM's strong potential to neutralize free radicals and mitigate oxidative damage [6].

Oxidative stress, primarily resulting from excessive ROS production, is implicated in the pathogenesis of neurodegenerative and chronic inflammatory diseases. BM mitigates these effects by directly scavenging ROS and enhancing the endogenous antioxidant system. It modulates redox-sensitive signaling pathways and prevents lipid peroxidation, protein denaturation, and DNA damage [5].

BM also exhibits significant anti-inflammatory activity. Phytocompounds such as quercetin from BM have been shown to reduce the expression of pro-inflammatory genes like cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages. This inhibition results in reduced nitric oxide (NO) production and downregulation of inflammatory mediators [7]. Network pharmacology and molecular docking analyses have revealed strong binding affinities of BM-derived compounds to key inflammation-related targets, including COX-2, iNOS, LOX, STAT3, CCR1, and MMP9, further validating its multi-targeted anti-inflammatory potential [7].

The suppression of inflammatory pathways by BM is also associated with reduced phosphorylation of nuclear factor kappa B (NF- κ B), a central transcription factor in the inflammatory response. This mechanism, coupled with decreased levels of cytokines such as interleukin-6 and tumor necrosis factor-alpha, positions BM as a promising agent for managing chronic neuroinflammation [5].

Collectively, the antioxidant and anti-inflammatory actions of *Bacopa monnieri* contribute substantially to

its therapeutic efficacy. These mechanisms help counteract oxidative and inflammatory insults that underlie many neurological and systemic pathologies, thereby supporting its traditional and modern medicinal applications.

3.3 Other Biological Mechanisms.

In addition to its known effects on cognitive function and antioxidant capacity, *Bacopa monnieri* has been shown to influence several other biological pathways that may contribute to its broad therapeutic potential. One of the lesser-known but clinically relevant mechanisms is its interaction with cytochrome P450 (CYP) enzymes. A study by Ramasamy et al. (2014) demonstrated that a standardized methanolic extract of *B. monnieri* exerts moderate inhibitory activity on several key human CYP isoforms, including CYP2C19, CYP2C9, CYP1A2, and CYP3A4. Notably, the extract showed the strongest inhibition against CYP2C19 ($IC_{50} = 23.67 \mu\text{g/mL}$) and CYP2C9 ($IC_{50} = 36.49 \mu\text{g/mL}$), suggesting that oral administration of *B. monnieri* may alter drug metabolism by suppressing intestinal CYP activity. Interestingly, isolated bacosides alone showed negligible inhibition, indicating that other components in the extract may be responsible for this effect [8].

Hepatoprotective activity is another important pharmacological aspect of *B. monnieri*. In an experimental study using a nitrobenzene-induced liver injury model in rats, Menon et al. (2010) observed that treatment with the plant's ethanolic extract significantly normalized elevated liver enzyme levels, including AST, ALT, and ALP. The extract also restored hepatic antioxidant enzyme levels, such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), while reducing lipid peroxidation. These findings were supported by histopathological observations, which showed reduced necrosis and inflammation in the liver tissues of extract-treated rats, indicating a clear hepatoprotective effect [9].

Further insights into the systemic protective mechanisms of *Bacopa monnieri* were reported in a recent study by Sivasangari et al. (2023), which explored the effects of prenatal stress and antioxidant interventions in a rodent model. Supplementation with a standardized *B. monnieri* extract (CDRI-08) in pregnant rats exposed to maternal stress resulted in significant protection of offspring from oxidative damage. The extract modulated the expression of genes related to antioxidant defenses (SOD1, SOD2, GPX3, CAT), and importantly, preserved telomere length and expression of telomere-related proteins such as telomerase reverse transcriptase (TERT), TRF1, RAP1B, and POT1. These findings suggest that *B. monnieri* may support genomic stability and delay cellular aging through maintenance of telomere biology [10].

In addition to its antioxidant and cytoprotection-related actions, *Bacopa monnieri* appears to exert a pronounced regulatory effect on the hypothalamic–pituitary–adrenal (HPA) axis. As shown in a study by Sivasangari and Rajan (2020), administration of standardized *B. monnieri* extract to pregnant rats exposed to prenatal stress significantly reduced circulating levels of corticosterone and adrenocorticotropic hormone

(ACTH) in their offspring. Moreover, it normalized the expression of glucocorticoid receptors in the amygdala, suggesting a rebalancing of stress-related hormonal signaling. These findings indicate that *B. monnieri* may modulate neuroendocrine responses to chronic stress by attenuating HPA axis hyperactivity, thus supporting its potential role as an adaptogen and stress-buffering agent [11].

In a related study, it was shown that bacosides may also exert protective effects against cellular toxicity induced by environmental carcinogens. Specifically, pretreatment with bacoside A mitigated hepatotoxicity and oxidative stress in diethylnitrosamine-exposed rats by maintaining the activity of key liver enzymes and enhancing the antioxidant defense system [9].

Together, these findings highlight the multifaceted role of *Bacopa monnieri* in modulating metabolic enzymes, protecting hepatic function, regulating oxidative stress responses, preserving genomic integrity, and reestablishing hormonal homeostasis, effects that extend beyond its classical nootropic and neuroprotective actions.

4. The Impact of Bacopa Monnieri Supplementation on Human Health.

4.1. Enhancement of Cognitive Functions and Memory – Review of Clinical and Preclinical Studies, Mechanisms.

Bacopa monnieri (BM), commonly known as Brahmi has long been used in traditional Ayurvedic medicine for its reputed nootropic properties. Recent clinical and preclinical investigations have sought to validate its efficacy, particularly concerning memory enhancement and cognitive function, with promising results across diverse age groups.

Clinical Evidence on Cognitive Enhancement

Several randomized controlled trials have demonstrated that *Bacopa monnieri* supplementation improves various aspects of memory, especially in aging populations. In a pivotal double-blind, placebo-controlled study by Roodenrys et al. (2002), 76 healthy participants aged 40–65 received 300 mg of *Bacopa* extract (KeenMind®) daily for 12 weeks. Results showed a significant improvement in retention of new information compared to placebo, with the most notable effect being a reduced rate of forgetting, though learning speed remained unaffected. Importantly, attention and working memory tasks were not significantly influenced, suggesting selective enhancement of long-term memory processes [12].

Similarly, Peth-Nui et al. (2012) conducted a 12-week randomized, double-blind, placebo-controlled trial on elderly volunteers (aged ~63 years) using 300 or 600 mg of *Bacopa* extract daily. The study revealed significant improvements in working memory (accuracy and reaction time), alongside decreased latencies in N100 and P300 ERP components – biomarkers of attention and cognitive processing speed. Notably, *Bacopa* was associated with suppression of acetylcholinesterase (AChE) activity, suggesting a cholinergic mechanism of action [13].

Furthermore, Best et al. (2024) investigated the effects of a polyphenolic-rich supplement containing Bacopa (300 mg), Panax quinquefolius (100 mg), and whole coffee fruit extract (100 mg) in a 28-day double-blind, placebo-controlled study in healthy middle-aged adults. Participants showed enhanced delayed recall and increased prefrontal cortex activation as measured by functional near-infrared spectroscopy (fNIRS), indicating improvements in working memory and emotional-cognitive processing. These results underscore the potential synergistic effects of Bacopa with other polyphenols in supporting cognitive reserve [14].

Preclinical Mechanisms of Action

The neurocognitive effects of Bacopa monnieri have been attributed to its major bioactive constituents – bacosides A and B – which exert several neuroprotective effects. Animal studies have demonstrated that these compounds enhance synaptic transmission, promote dendritic growth, and reduce oxidative stress in key brain areas involved in memory, including the hippocampus and frontal cortex (Bhattacharya et al., 2000).

Further, Bacopa extract mitigates memory impairment in rats caused by scopolamine, electroshock, and immobilization. These findings suggest a cholinergic mode of action, supported by the observed inhibition of AChE activity in both animals and humans, thus enhancing cholinergic transmission—a key pathway in memory and attention regulation [12], [13].

4.2 Effects of Bacopa monnieri Supplementation on Mood Disorders: Anxiety and Depression — Study Results in Healthy Individuals and Those with Disorders.

Bacopa monnieri (BM), a traditional Ayurvedic herb, has shown promise in addressing mood disorders such as anxiety and depression. Clinical studies examining its efficacy have yielded mixed but insightful results, both in healthy populations and individuals with mood disturbances.

Effects in Healthy Individuals

Several placebo-controlled trials have investigated the influence of BM on anxiety levels in healthy adults. In a randomized double-blind study by Sathyanarayanan et al. (2013), 72 healthy adults received 450 mg of Bacopa monnieri extract daily for 12 weeks. While no statistically significant improvements were observed in cognitive parameters, there was a trend toward reduced state anxiety in the BM group compared to placebo, indicating potential anxiolytic properties that may not have reached full effect within the study's timeframe or sample size limitations [15].

Earlier studies had reported more favorable results. Stough et al. (2001) found significant improvements in state anxiety and cognitive performance in healthy volunteers administered 300 mg/day of BM extract over 12 weeks. These results were later echoed by Calabrese et al. (2008), who noted a reduction in both state and trait anxiety, as well as depressive symptoms, in elderly participants taking 300 mg/day of standardized BM

extract. In that study, participants receiving BM showed decreased scores on the CESD-10 depression scale and combined anxiety scores (STAI), while placebo group scores increased over the 12-week period [16].

However, not all studies have shown consistent benefits. A systematic review by Pase et al. (2012) found moderate evidence for BM's enhancement of memory recall but highlighted insufficient or inconsistent evidence for its effects on broader cognitive or affective domains, including anxiety [15].

Effects in Individuals with Mood Disorders

In contrast to studies on healthy individuals, preclinical and some limited clinical studies involving subjects with mood disturbances suggest more robust effects. According to Brimson et al. (2021), animal studies using chronic unpredictable stress (CUS) models—a common proxy for human depression—demonstrated that BM administration restored hippocampal brain-derived neurotrophic factor (BDNF) expression, enhanced neurogenesis, and reduced corticosterone levels. These effects mirrored those of imipramine, a conventional antidepressant, suggesting that BM may act through similar pathways, including possible sigma-1 receptor modulation. Further supporting this, BM improved depressive-like behavior in animal models such as the Porsolt forced swim test and tail suspension test. Notably, these effects were more pronounced with chronic rather than acute treatment, indicating the importance of long-term use for therapeutic benefits. Despite these promising findings, high-quality clinical studies directly evaluating BM's impact on clinically diagnosed depression and anxiety remain scarce. One human study cited by Brimson et al. (2021) found that BM, when used as part of a multi-herbal supplement alongside conventional antidepressants, enhanced treatment outcomes in patients with mild cognitive impairment and depressive symptoms. However, due to the combined formulation, the effects cannot be solely attributed to BM [17].

4.3. Effects on the Cardiovascular System – Studies on Blood Pressure and Lipid Profile.

Bacopa monnieri (BM), a traditional Ayurvedic herb, has been shown to exert significant effects on cardiovascular health, particularly in relation to blood pressure regulation, vascular function, and myocardial protection. Although studies in humans are limited, preclinical animal models provide substantial evidence supporting its cardiovascular benefits.

One of the principal findings regarding BM is its hypotensive effect. In a study conducted on anaesthetized rats, intravenous administration of BM extract (20–60 mg/kg) significantly reduced both systolic and diastolic blood pressure without affecting heart rate. The hypotensive action was attributed to vasodilation mediated by endothelium-derived nitric oxide (NO) and direct effects on calcium homeostasis in vascular smooth muscle. Notably, BM inhibited both extracellular calcium influx and sarcoplasmic reticulum calcium release, mechanisms essential for vascular tone regulation. Two saponins found in BM, bacoside A3 and bacoside II, demonstrated vasorelaxant effects,

supporting the extract's potential as a natural antihypertensive agent [18].

Beyond its influence on vascular tone, BM has also demonstrated cardioprotective effects in models of ischemia–reperfusion (I/R) injury. In a Langendorff rat heart preparation, oral pretreatment with BM (75 mg/kg for three weeks) significantly mitigated I/R-induced myocardial damage. This was evident through improvements in cardiac histopathology, reductions in infarct size, and favorable modulation of apoptotic pathways. Specifically, BM enhanced the expression of anti-apoptotic Bcl-2 protein while reducing pro-apoptotic Bax and caspase-3 activity, alongside increasing antioxidant enzyme levels such as superoxide dismutase (SOD), catalase, and glutathione peroxidase [19].

Complementary findings were reported in another Langendorff model, where acute perfusion of BM extract (30–100 µg/ml) in isolated hearts increased coronary flow by up to 216%, improved left ventricular developed pressure, and reduced infarct volume by more than 50% compared to controls. These effects were accompanied by a significant reduction in L-type calcium current (ICa,L) in HL-1 cardiomyocytes, suggesting a direct cardiomyocyte protective mechanism [20].

Although lipid profile changes were not the primary focus of these studies, the observed improvements in myocardial antioxidant status and reduced lipid peroxidation (measured via TBARS) imply indirect benefits to lipid metabolism and cardiovascular integrity [19].

In conclusion, *Bacopa monnieri* exhibits promising cardiovascular effects, particularly in reducing blood pressure and protecting against ischemic injury. These findings highlight its potential as a complementary agent in managing cardiovascular risk, though further clinical studies are required to confirm efficacy in humans and evaluate its effects on lipid profile.

4.4. Other Potential Health Benefits of *Bacopa monnieri* – Immunomodulatory, Sleep-Enhancing, and Adaptogenic Effects.

In addition to its well-established cognitive-enhancing effects, *Bacopa monnieri* (BM) exhibits a range of other promising health benefits, including immunomodulatory, adaptogenic, and possible sleep-improving properties. These effects are increasingly relevant in the context of stress-related diseases, inflammation-driven disorders, and general wellbeing.

Immunomodulatory and Anti-inflammatory Activity

BM has demonstrated significant immunomodulatory effects, primarily via its anti-inflammatory properties. In vitro studies show that BM suppresses key pro-inflammatory mediators such as nitric oxide (NO), tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ) in stimulated macrophages and human whole blood cells [21], [22]. At the same time, BM slightly increased levels of the anti-inflammatory cytokine interleukin-10 (IL-10), suggesting a shift toward a regulatory T-cell response, which could be

beneficial in chronic inflammatory and autoimmune conditions [22].

Moreover, BM inhibits the activity of cyclooxygenase-2 (COX-2), a key enzyme involved in the synthesis of inflammatory prostaglandins. This inhibition may underlie its neuroprotective effects and potential in managing conditions like Alzheimer's disease, where chronic neuroinflammation is a contributing factor [22].

Adaptogenic Properties

BM has been extensively studied for its **adaptogenic activity**, defined as the ability to increase an organism's resistance to stress. In animal models, BM significantly reversed stress-induced physiological alterations caused by both acute and chronic immobilization stress. This includes reductions in ulcer index, adrenal hypertrophy, and elevated plasma biomarkers such as glucose, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and creatine kinase (CK) [21]. The efficacy was dose-dependent, with higher doses (80 mg/kg) showing significant restoration of stress-induced abnormalities.

Human studies also support this role. An acute, double-blind, placebo-controlled crossover study found that 320 mg and 640 mg doses of BM (CDRI 08 extract) reduced salivary cortisol and improved cognitive performance and mood during a multitasking stress test [23]. These findings highlight BM's ability to modulate the hypothalamic-pituitary-adrenal (HPA) axis and buffer physiological responses to psychological stress.

Potential Sleep-Enhancing Effects

Although sleep-specific studies on BM are limited, indirect evidence suggests it may influence sleep quality through its stress-reducing and mood-modulating properties. BM's role in lowering cortisol levels and enhancing emotional wellbeing under stress suggests it could contribute to improved sleep regulation, especially in populations with stress-related sleep disturbances [23].

Furthermore, chronic low-grade inflammation and oxidative stress are known disruptors of sleep architecture. BM's anti-inflammatory and antioxidant actions might, therefore, help restore normal sleep physiology, although more direct clinical trials are needed to confirm this effect [22].

5. Safety and Side Effects of *Bacopa monnieri* Supplementation.

5.1. Review of Toxicological and Clinical Studies: Is *Bacopa* Safe?

Bacopa monnieri has been extensively evaluated for its safety profile in both animal and human studies. Toxicological assessments reveal that standardized extracts such as Bacognize® and BacoMind® exhibit no significant genotoxic or subchronic toxicity effects. A 90-day oral toxicity study in rats determined a No-Observed-Adverse-Effect-Level (NOAEL) at doses up to 1000 mg/kg/day, with no clinically relevant changes in behavior, weight, organ histology, hematology, or biochemistry observed during treatment [24].

In clinical settings, *Bacopa* was also shown to be well tolerated. A systematic review in children and

adolescents reported mild side effects, indicating a favorable safety profile even in younger populations [25]. Additionally, trials involving healthy adults showed no adverse effects with standardized extracts dosed at 300–450 mg/day [24].

5.2. Potential Drug Interactions.

Bacopa monnieri may influence the metabolism of concurrently administered drugs, especially those metabolized by cytochrome P450 enzymes. A 2014 in vitro study revealed that *Bacopa* extract significantly inhibits CYP3A4, CYP2C9, CYP2C19, and CYP1A2, while showing weak inhibition on CYP2D6. These enzymes are responsible for metabolizing many psychoactive, anticoagulant, and cardiovascular drugs [8]. Following oral administration, intestinal concentrations of *Bacopa monnieri* extract are expected to exceed the reported IC₅₀ values for CYP3A4, CYP2C9, and CYP2C19 inhibition, indicating substantial potential for intestinal CYP suppression and clinically relevant herb–drug interactions [8].

Clinicians should therefore exercise caution when *Bacopa* is co-administered with substrates of these enzymes, such as SSRIs, benzodiazepines, warfarin, or statins. Though bacosides (the active compounds) themselves had negligible effects on CYP enzymes, the full plant extract poses greater interaction risks [8].

5.3. Dosage and Recommendations.

In clinical practice, standardized *Bacopa* extracts are commonly administered at daily doses ranging from 300 to 450 mg. These doses are typically standardized to contain 20–55% bacosides and are used in divided doses (e.g., 150 mg twice daily). Most clinical trials demonstrating cognitive and neuroprotective effects have utilized doses within this range, often over extended periods (6–12 weeks or longer) to observe benefits [17].

For children and adolescents, lower doses (e.g., 225–300 mg/day) have been effective and well tolerated [25]. Importantly, the therapeutic effects of *Bacopa* may take weeks to become evident, reflecting its adaptogenic and cumulative pharmacological nature.

6. Conclusion.

Bacopa monnieri represents a promising herbal agent with diverse pharmacological actions that align closely with its traditional uses in Ayurvedic medicine. The growing body of scientific evidence highlights its capacity to enhance memory, support neurogenesis, and mitigate stress-related cognitive and mood disturbances. Its antioxidant and anti-inflammatory effects further broaden its therapeutic scope, offering protection against oxidative damage, neuroinflammation, and systemic conditions such as cardiovascular and liver disorders. Clinical and preclinical studies confirm that *Bacopa monnieri* can modulate crucial biological pathways, including cholinergic neurotransmission, neurotrophic signaling, the HPA axis, and even telomere biology. These findings support the herb's potential use in both preventive and therapeutic contexts, particularly for populations at risk of cognitive decline or chronic stress exposure.

Importantly, *Bacopa monnieri* has demonstrated a favorable safety profile, with minimal adverse effects reported in both children and adults. Nevertheless, potential herb–drug interactions related to cytochrome P450 enzyme inhibition should be carefully considered, especially in individuals on polypharmacy.

In summary, *Bacopa monnieri* offers a multi-targeted, evidence-based approach to improving mental performance, emotional wellbeing, and systemic resilience. Continued research is warranted to further elucidate its mechanisms, optimize formulations, and confirm long-term efficacy and safety in larger and more diverse patient populations.

Disclosure

Author's contribution

Conceptualization: Anna Maria Modzelewska, Michał Szczupak

Methodology: Michał Wycik, Kinga Rydel, Wiktor Modzelewski

Software: Michał Szczupak, Michał Wycik, Anna Maria Modzelewska

Formal analysis: Urban Stanisław Matyjasik, Gabriela Kondratiuk

Investigation: Gabriela Kondratiuk, Martyna Tyszko, Julia Komar

Writing – rough preparation: Hubert Chmielewski, Adam Zysk, Wiktor Modzelewski

Writing – review and editing: Julia Komar, Hubert Chmielewski, Urban Stanisław Matyjasik

Supervision: Martyna Tyszko, Adam Zysk, Kinga Rydel

Receiving funding - no specific funding

All authors have read and agreed with the published version of the manuscript.

Funding statement

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflict of interest

The authors deny any conflict of interest.

REFERENCES

1. M. A. Hurraira, M. Abdullah, A. Mansur, and M. R. Kuddus, "Phytochemical and Biological Investigations of *Bacopa monnieri* L.," *Dhaka University Journal of Pharmaceutical Sciences*, vol. 22, no. 2, pp. 155–161, Dec. 2023, doi: 10.3329/DUJPS.V22I2.67407.
2. C. Mittal, M. Mondal, and S. Chatterjee, "A review: Phytochemistry and medicinal activities of *Bacopa monnieri*", doi: 10.33545/26174693.2025.v9.i3g.3996.
3. H. Thi *et al.*, "Bacopa monnieri (L.) Wettst. Extract Improves Memory Performance via Promotion of

- Neurogenesis in the Hippocampal Dentate Gyrus of Adolescent Mice”, doi: 10.3390/ijms21093365.
4. M. Bychowski *et al.*, “Recent Advances in Bacopa Monnieri Research: Neuroprotective Effects and Cognitive Decline Mitigation in Neurodegenerative Diseases with a Focus on Alzheimer’s and Parkinson’s Diseases,” *Quality in Sport*, vol. 35, p. 56377, Dec. 2024, doi: 10.12775/QS.2024.35.56377.
5. L. J. Valotto Neto *et al.*, “Investigating the Neuroprotective and Cognitive-Enhancing Effects of Bacopa monnieri: A Systematic Review Focused on Inflammation, Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis,” *Antioxidants* 2024, Vol. 13, Page 393, vol. 13, no. 4, p. 393, Mar. 2024, doi: 10.3390/ANTIOX13040393.
6. R. Shanmugam *et al.*, “A Quantitative Analysis of in vitro Antioxidant Capacity and Antioxidant Enzymes in Bacopa monnieri (L.) Wettst,” *Free Radicals and Antioxidants*, vol. 14, no. 2, pp. 97–103, Jan. 2024, doi: 10.5530/FRA.2024.2.9.
7. R. Jeyasri, P. Muthuramalingam, S. Adarshan, H. Shin, and M. Ramesh, “Assessing the Anti-inflammatory Effects of Bacopa-Derived Bioactive Compounds Using Network Pharmacology and in Vitro Studies,” *ACS Omega*, vol. 7, no. 44, pp. 40344–40354, Nov. 2022, doi: 10.1021/ACSOMEGA.2C05318/ASSET/IMAGES/LARGE/AO2C05318_0009.JPEG.
8. S. Ramasamy, L. V. Kiew, and L. Y. Chung, “Inhibition of human cytochrome P450 enzymes by Bacopa monnieri standardized extract and constituents,” *Molecules*, vol. 19, no. 2, pp. 2588–2601, Feb. 2014, doi: 10.3390/MOLECULES19022588.
9. B. R. Menon, M. A. Rathi, L. Thirumoorathi, and V. K. Gopalakrishnan, “Potential Effect of Bacopa monnieri on Nitrobenzene Induced Liver Damage in Rats,” *Indian J Clin Biochem*, vol. 25, no. 4, pp. 401–404, Sep. 2010, doi: 10.1007/S12291-010-0048-4.
10. K. Sivasangari, B. S. Sivamaruthi, C. Chaiyasut, and K. E. Rajan, “Maternal stress-induced changes in adolescent and adult offspring: Neurobehavioural improvement and telomere maintenance,” *Heliyon*, vol. 9, no. 10, p. e20385, Oct. 2023, doi: 10.1016/J.HELİYON.2023.E20385.
11. K. Sivasangari and K. E. Rajan, “Standardized Bacopa monnieri Extract Ameliorates Learning and Memory Impairments through Synaptic Protein, Neurogranin, Pro-and Mature BDNF Signaling, and HPA Axis in Prenatally Stressed Rat Offspring,” *Antioxidants* 2020, Vol. 9, Page 1229, vol. 9, no. 12, p. 1229, Dec. 2020, doi: 10.3390/ANTIOX9121229.
12. S. Roodenrys, “Chronic Effects of Brahmi (Bacopa monnieri) on Human Memory,” 2002. [Online]. Available: www.acnp.org/citations/
13. T. Peth-Nui *et al.*, “Effects of 12-week bacopa monnieri consumption on attention, cognitive processing, working memory, and functions of both cholinergic and monoaminergic systems in healthy elderly volunteers,” *Evidence-based Complementary and Alternative Medicine*, vol. 2012, 2012, doi: 10.1155/2012/606424.
14. V. Sathyanarayanan, T. Thomas, S. J. L. Einöther, R. Dobriyal, M. K. Joshi, and S. Krishnamachari, “Brahmi for the better? New findings challenging cognition and anti-anxiety effects of Brahmi (Bacopa monnieri) in healthy adults,” *Psychopharmacology (Berl)*, vol. 227, no. 2, pp. 299–306, May 2013, doi: 10.1007/s00213-013-2978-z.
15. C. Calabrese, W. L. Gregory, M. Leo, D. Kraemer, K. Bone, and B. Oken, “Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: A randomized, double-blind, placebo-controlled trial,” *Journal of Alternative and Complementary Medicine*, vol. 14, no. 6, pp. 707–713, Jul. 2008, doi: 10.1089/acm.2008.0018.
16. J. M. Brimson, S. Brimson, M. I. Prasanth, P. Thitilertdech, D. S. Malar, and T. Tencomnao, “The effectiveness of Bacopa monnieri (Linn.) Wettst. as a nootropic, neuroprotective, or antidepressant supplement: analysis of the available clinical data,” *Sci Rep*, vol. 11, no. 1, Dec. 2021, doi: 10.1038/s41598-020-80045-2.
17. N. Kamkaew *et al.*, “Bacopa monnieri and its constituents is hypotensive in anaesthetized rats and vasodilator in various artery types,” *J Ethnopharmacol*, vol. 137, no. 1, pp. 790–795, Sep. 2011, doi: 10.1016/j.jep.2011.06.045.
18. I. R. Mohanty, U. Maheshwari, D. Joseph, and Y. Deshmukh, “Bacopa monnieri protects rat heart against ischaemia-reperfusion injury: Role of key apoptotic regulatory proteins and enzymes,” *Journal of Pharmacy and Pharmacology*, vol. 62, no. 9, pp. 1175–1184, Sep. 2010, doi: 10.1111/j.2042-7158.2010.01155.x.
19. S. Srimachai *et al.*, “Bacopa monnieri extract increases rat coronary flow and protects against myocardial ischemia/reperfusion injury,” *BMC Complement Altern Med*, vol. 17, no. 1, Feb. 2017, doi: 10.1186/s12906-017-1637-z.
20. D. Rai, G. Bhatia, G. Palit, R. Pal, S. Singh, and H. K. Singh, “Adaptogenic effect of Bacopa monnieri (Brahmi),” *Pharmacol Biochem Behav*, vol. 75, no. 4, pp. 823–830, 2003, doi: 10.1016/S0091-3057(03)00156-4.
21. R. Williams, G. Münch, E. Gyengesi, and L. Bennett, “Bacopamonnieri (L.) exerts anti-inflammatory effects on cells of the innate immune system in vitro,” *Food Funct*, vol. 5, no. 3, pp. 517–520, 2014, doi: 10.1039/c3fo60467e.
22. S. Benson, L. A. Downey, C. Stough, M. Wetherell, A. Zangara, and A. Scholey, “An acute, double-blind, placebo-controlled cross-over study of 320 mg and 640 mg doses of Bacopa monnieri (CDRI 08) on multitasking stress reactivity and mood,” *Phytotherapy Research*, vol. 28, no. 4, pp. 551–559, 2014, doi: 10.1002/ptr.5029.
23. J. Muchhara *et al.*, “Safety evaluation of the genotoxicity and subchronic toxicity of standardized Bacopa extract (Bacognize®) from Bacopa monnieri,” *Toxicology Research and Application*, vol. 7, Jan. 2023, doi: 10.1177/23978473231162859.

24. J. D. Kean, L. A. Downey, and C. Stough, "A systematic review of the Ayurvedic medicinal herb *Bacopa monnieri* in child and adolescent populations," Dec. 01, 2016, *Churchill Livingstone*. doi: 10.1016/j.ctim.2016.09.002.